Ellington Management Group’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Ellington Management Group’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-9,900	Closed	-$344K	–	866
2019 Q1	$344K	Buy	+9,900	New	+$286K	0.06%	320
2017 Q1	–	Sell	-15,900	Closed	-$357K	–	940
2016 Q4	$357K	Buy	+15,900	New	+$311K	0.05%	295

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Ellington Management Group's PTLA Position: Q2 2019 in Review

Ellington Management Group sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2019, closing a stake of 9,900 shares — an estimated $344K sold.

Ellington Management Group first reported a position in PTLA in Q4 2016 and held it in 2 quarters. The position peaked at $357K in Q4 2016. 201 funds tracked by Wall St. Rank hold PTLA as of Q2 2019.

Ellington Management Group reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Ellington Management Group sold 9,900 Portola Pharmaceuticals, Inc. shares in Q2 2019, an estimated $344K.
Ellington Management Group first reported a position in Portola Pharmaceuticals, Inc. in Q4 2016 and held it in 2 quarters.
Ellington Management Group's Portola Pharmaceuticals, Inc. position peaked at $357K in Q4 2016.
201 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2019.

Based on Ellington Management Group's 13F filing for Q2 2019, filed 14 Aug 2019.